Goldman Sachs Group Inc Biomarin Pharmaceutical Inc Put Options Transaction History

Goldman Sachs Group Inc

5 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2022 May 14, 2024	SELL	$82.16 - $96.94 $230,048 - $271,432	-2,800 Reduced 8.56%	29,900 $2.54 Million
Q3 2022 Nov 10, 2022	SELL	$82.16 - $96.94 $230,048 - $271,432	-2,800 Reduced 8.56%	29,900 $2.53 Million
Q2 2022 May 14, 2024	BUY	$71.48 - $86.85 $2.34 Million - $2.84 Million	32,700 New	32,700 $2.71 Million
Q2 2022 Aug 15, 2022	SELL	$71.48 - $86.85 $3.95 Million - $4.8 Million	-55,300 Reduced 62.84%	32,700 $2.71 Million
Q3 2021 Nov 10, 2021	BUY	$74.77 - $85.47 $6.58 Million - $7.52 Million	88,000 New	88,000 $6.8 Million

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.